Can I get Foundayo on the NHS?

Not currently. It is licensed but not NHS-funded, and NICE guidance is expected on 18 November 2026.

What does it cost privately?

Reported figures at launch ranged from roughly £99 to £179 a month depending on strength and provider. Launch pricing commonly changes.

Why is it licensed but not available on the NHS?

Licensing and funding are separate decisions. The MHRA assesses safety and efficacy; NICE assesses cost-effectiveness afterwards.

Research & Regulatory News

Orforglipron in the UK: Access, Cost and the NHS Question

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Foundayo holds a UK marketing authorisation but is not funded by the NHS. Access is currently through private prescription after clinical assessment, with reported monthly costs ranging from about £99 to £179 depending on strength and provider. NHS availability depends on NICE guidance expected on 18 November 2026.

Key facts

Authorised: 10 August 2026 (MHRA)
Route to access: Private prescription after clinical assessment
Reported monthly cost: Approximately £99–£179
NHS status: Not funded
NICE guidance expected: 18 November 2026
Likely NHS prescribing: Not before 2027 if recommended

Authorisation is not availability

These are two separate decisions made by two separate bodies. The MHRA assesses whether a medicine is safe, effective and of adequate quality, and grants a marketing authorisation on that basis. Whether the NHS pays for it is decided afterwards by NICE, which assesses cost-effectiveness. A medicine can be fully licensed in the UK and still be unavailable on the NHS for a year or more, which is precisely the position Foundayo is in.

What access looks like at the moment

Supply is through registered pharmacies on private prescription, following a clinical assessment against the licensed criteria — a BMI of 30 or above, or 27 to 30 with at least one weight-related comorbidity. Reported monthly costs have ranged from around £99 for lower strengths to roughly £149–£179 at higher strengths, varying by provider. Prices reported at launch tend to move.

What NICE is deciding

NICE guidance is expected on 18 November 2026. The appraisal weighs clinical effectiveness against cost per quality-adjusted life year, and considers the size of the eligible population — which for obesity medicines is very large, and is the reason previous incretin appraisals have come with tight eligibility criteria and managed-access arrangements rather than open prescribing.

Why the tablet format matters commercially

Orforglipron is manufactured by conventional organic synthesis rather than peptide synthesis or recombinant expression. That is substantially cheaper and easier to scale, and supply constraints have been a real limitation on injectable incretins. Cost-effectiveness arguments at NICE turn partly on price, and a compound without a peptide manufacturing bottleneck has more room on that axis.

A necessary distinction

Foundayo is a prescription-only medicine, assessed and supplied through regulated clinical channels. It is not related to research material, and nothing supplied for laboratory research is an alternative to it, a generic of it, or a route to obtaining it. We do not supply it and this article is not a purchasing guide.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Can I get Foundayo on the NHS?: Not currently. It is licensed but not NHS-funded, and NICE guidance is expected on 18 November 2026.
What does it cost privately?: Reported figures at launch ranged from roughly £99 to £179 a month depending on strength and provider. Launch pricing commonly changes.
Why is it licensed but not available on the NHS?: Licensing and funding are separate decisions. The MHRA assesses safety and efficacy; NICE assesses cost-effectiveness afterwards.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum